We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+0.68%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$10.2B
AUM Growth
-$819M
Cap. Flow
-$1.84B
Cap. Flow %
-18.03%
Top 10 Hldgs %
83.92%
Holding
140
New
7
Increased
13
Reduced
18
Closed
7

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$96.9M
2
ONC
BeOne Medicines Ltd
ONC
+$55.3M
3
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$38.3M
4
AKAO
Achaogen Inc
AKAO
+$30.7M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$16.8M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$773M
2
EXEL icon
Exelixis
EXEL
+$27.8M
3
TGTX icon
TG Therapeutics
TGTX
+$15.5M
4
ARWR icon
Arrowhead Research
ARWR
+$13.6M
5
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.85%
2 Miscellaneous 12.14%
3 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
26
DELISTED
Merus
MRUS
$24.5M 0.24%
1,160,014
– –
XNCR icon
27
Xencor
XNCR
$1.82B
$23M 0.23%
872,072
– –
ARRY
28
DELISTED
Array Biopharma Inc
ARRY
$22.7M 0.22%
2,585,913
-724,753
-22% -$5.33M
BLUE
29
DELISTED
bluebird bio
BLUE
$21.7M 0.21%
27,131
+4,439
+20% +$3.52M
ASND icon
30
Ascendis Pharma A/S
ASND
$17.4B
$20.7M 0.2%
1,023,266
+277,745
+37% +$5.55M
DSCI
31
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$19.5M 0.19%
3,752,390
– –
LKFT
32
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.75B
$16.7M 0.16%
259,894
– –
ACGN
33
DELISTED
Aceragen Inc
ACGN
$15.4M 0.15%
9,451
+2,998
+46% +$5.72M
AVXS
34
DELISTED
AveXis, Inc. Common Stock
AVXS
$15M 0.15%
+315,300
New +$16.8M
NTLA icon
35
Intellia Therapeutics
NTLA
$1.66B
$13.9M 0.14%
1,062,120
– –
AIMT
36
DELISTED
Aimmune Therapeutics
AIMT
$13.8M 0.14%
673,908
– –
HALO icon
37
Halozyme
HALO
$12.3B
$13.7M 0.13%
1,391,507
-339,550
-20% -$3.72M
NDRM
38
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$12.7M 0.12%
571,667
+266,667
+87% +$4.99M
SGMO
39
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$12.4M 0.12%
4,055,876
– –
AERI
40
DELISTED
Aerie Pharmaceuticals
AERI
$11.3M 0.11%
299,356
– –
MRTX
41
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$10.8M 0.11%
2,269,198
– –
SAGE
42
DELISTED
Sage Therapeutics
SAGE
$10.6M 0.1%
208,328
– –
ZGNX
43
DELISTED
Zogenix, Inc.
ZGNX
$10.2M 0.1%
838,809
-161,191
-16% -$1.77M
DERM
44
DELISTED
Dermira, Inc.
DERM
$9.9M 0.1%
326,428
– –
ITCI
45
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.19M 0.09%
609,166
– –
ALKS icon
46
Alkermes
ALKS
$7.69B
$8.35M 0.08%
150,251
-100,000
-40% -$5.35M
ABEO icon
47
Abeona Therapeutics
ABEO
$311M
$8.17M 0.08%
67,375
+63,308
+1,557% +$9.91M
ACHN
48
DELISTED
Achillion Pharmaceuticals
ACHN
$7.67M 0.08%
1,856,637
-618,878
-25% -$3.29M
LGND icon
49
Ligand Pharmaceuticals
LGND
$5.59B
$7.46M 0.07%
117,638
– –
MGNX icon
50
MacroGenics
MGNX
$268M
$7.43M 0.07%
363,676
– –
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q4 2016 Portfolio in Review

As of Q4 2016, Baker Bros. Advisors held 140 positions worth $10.2B, down 7.4% from $11B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors withdrew a net $1.84B in Q4 2016, closing 7 positions and reducing 18 holdings. Its most notable exit was TG Therapeutics, an estimated $15.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Baker Bros. Advisors opened a new position in AveXis, Inc. Common Stock worth $15M.

  • Baker Bros. Advisors's largest Q4 2016 buy was AveXis, Inc. Common Stock: 315,300 shares worth $15M.
  • Baker Bros. Advisors added most to Seagen Inc. Common Stock in Q4 2016, an estimated $96.9M increase.
  • Baker Bros. Advisors's biggest Q4 2016 reduction was AbbVie, cutting an estimated $773M.
  • Baker Bros. Advisors fully exited TG Therapeutics in Q4 2016, selling an estimated $15.5M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $10.2B portfolio in Q4 2016.
  • Baker Bros. Advisors opened 7 new positions and closed 7 in Q4 2016.
  • Baker Bros. Advisors's portfolio value fell 7.4% quarter-over-quarter to $10.2B.

Based on Baker Bros. Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.